Levigress 1000 Tablet PR contains Levetiracetam 1000 mg, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. The prolonged-release formulation ensures a steady plasma concentration, enhancing patient compliance by allowing once or twice daily dosing. Levigress 1000 Tablet PR is typically used as adjunctive therapy but may be employed as monotherapy depending on clinical judgment. It is well tolerated, with common adverse effects including somnolence, dizziness, headache, and fatigue. Dose adjustments may be necessary in patients with renal impairment to prevent accumulation and toxicity. Caution is advised in patients with a history of psychiatric disorders, as mood changes and behavioral symptoms have been reported. Regular monitoring of clinical response and adverse effects is essential to optimize therapy. Levigress 1000 Tablet PR should be prescribed and administered under medical supervision, with adherence to recommended dosing guidelines to ensure efficacy and safety in seizure management.